 iStockAnalyst | Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled ... PharmaLive (press release) (subscription) Product candidate is being investigated as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Melphalan has been granted Orphan designation by the FDA for this indication. In a previous Phase 2 study, ... Spectrum Pharma (SPPI) Gains Development, Commercialization Rights To ... |
